Insights into the role of endostatin in obesity. (September 2019)
- Record Type:
- Journal Article
- Title:
- Insights into the role of endostatin in obesity. (September 2019)
- Main Title:
- Insights into the role of endostatin in obesity
- Authors:
- Nijhawan, Priya
Makkar, Rashita
Gupta, Amit
Arora, Sandeep
Garg, Madhular
Behl, Tapan - Abstract:
- Abstract: Objective: The role of endostatin has come out as an emerging remedy in control and treatment of numerous metabolic disorders. This review highlights the intricate role in obesity and its associated complications. Key findings: Through recent studies and reports the role of various epigenetic markers in the treatment of obesity has been revealed. Neovascularization and adipogenesis produce various angiogenic factors including leptin, angiopoietins, VEGF (Vascular endothelial growth factor) and TGF-β (Transforming growth factor beta) during expansion of adipose tissue via paracrine signaling pathway, therefore angiogenesis has been recognized as a major therapeutic target of obesity. It has been stated that endostatin has been identified as a potent inhibitor of adipogenesis and dietary-induced obesity. However, the mechanism of endostatin is still unclear but its act on Sam68 RNA in preadipocytes by binding to it and this in turn prevents the interaction of Sam68 to intron 5 in mTOR resulting in decreases the expression of mTOR. Moreover, it has been demonstrated that the antiangiogenic property of endostatin prevents obesity and its related metabolic disorders, including insulin resistance, glucose intolerance, and hepatic steatosis and inhibit the combined functions on angiogenesis and adipogenesis. Summary: The present review focus on the intrinsic role of endostatin as an emerging remedy in the treatment of obesity and its related complications demonstratingAbstract: Objective: The role of endostatin has come out as an emerging remedy in control and treatment of numerous metabolic disorders. This review highlights the intricate role in obesity and its associated complications. Key findings: Through recent studies and reports the role of various epigenetic markers in the treatment of obesity has been revealed. Neovascularization and adipogenesis produce various angiogenic factors including leptin, angiopoietins, VEGF (Vascular endothelial growth factor) and TGF-β (Transforming growth factor beta) during expansion of adipose tissue via paracrine signaling pathway, therefore angiogenesis has been recognized as a major therapeutic target of obesity. It has been stated that endostatin has been identified as a potent inhibitor of adipogenesis and dietary-induced obesity. However, the mechanism of endostatin is still unclear but its act on Sam68 RNA in preadipocytes by binding to it and this in turn prevents the interaction of Sam68 to intron 5 in mTOR resulting in decreases the expression of mTOR. Moreover, it has been demonstrated that the antiangiogenic property of endostatin prevents obesity and its related metabolic disorders, including insulin resistance, glucose intolerance, and hepatic steatosis and inhibit the combined functions on angiogenesis and adipogenesis. Summary: The present review focus on the intrinsic role of endostatin as an emerging remedy in the treatment of obesity and its related complications demonstrating their use in the inhibition of angiogenesis event, adipogenesis and provide protection against the release of angiogenic factors. Highlights: Angiogenesis and adipogenesis play an important role on obesity. There exists a function link between angiogenesis and adipogenesis. Endostatin inhibits angiogenesis. … (more)
- Is Part Of:
- Obesity medicine. Volume 15(2019)
- Journal:
- Obesity medicine
- Issue:
- Volume 15(2019)
- Issue Display:
- Volume 15, Issue 2019 (2019)
- Year:
- 2019
- Volume:
- 15
- Issue:
- 2019
- Issue Sort Value:
- 2019-0015-2019-0000
- Page Start:
- Page End:
- Publication Date:
- 2019-09
- Subjects:
- Obesity -- Endostatin -- Angiogenesis -- PPARγ -- Adipogenesis -- VEGF
Obesity -- Periodicals
Obesity
Obesity
Periodicals
Periodicals
616.398005 - Journal URLs:
- https://www.clinicalkey.com/dura/browse/journalIssue/24518476 ↗
http://www.sciencedirect.com/science/journal/24518476 ↗
http://www.sciencedirect.com/ ↗ - DOI:
- 10.1016/j.obmed.2019.100120 ↗
- Languages:
- English
- ISSNs:
- 2451-8476
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 11628.xml